Sheng Cheng

1.1k total citations · 2 hit papers
26 papers, 709 citations indexed

About

Sheng Cheng is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Sheng Cheng has authored 26 papers receiving a total of 709 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Cancer Research and 4 papers in Surgery. Recurrent topics in Sheng Cheng's work include MicroRNA in disease regulation (7 papers), Circular RNAs in diseases (6 papers) and Asthma and respiratory diseases (3 papers). Sheng Cheng is often cited by papers focused on MicroRNA in disease regulation (7 papers), Circular RNAs in diseases (6 papers) and Asthma and respiratory diseases (3 papers). Sheng Cheng collaborates with scholars based in China, United States and Germany. Sheng Cheng's co-authors include Huilong Chen, Zhilin Zeng, Juan Zhan, Liyuan Chen, Kaimin Zhang, Gonghui Li, Liqun Xia, Zeyi Lu, Ruyue Wang and Lifeng Ding and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biochemical and Biophysical Research Communications and Cancer Letters.

In The Last Decade

Sheng Cheng

25 papers receiving 699 citations

Hit Papers

Global, regional, and national dengue burden from 1990 to... 2021 2026 2022 2024 2021 2022 50 100 150

Peers

Sheng Cheng
Samy Zaky Egypt
Julia A. Messina United States
Eun Sil Kim South Korea
Yang Luan China
Samy Zaky Egypt
Sheng Cheng
Citations per year, relative to Sheng Cheng Sheng Cheng (= 1×) peers Samy Zaky

Countries citing papers authored by Sheng Cheng

Since Specialization
Citations

This map shows the geographic impact of Sheng Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheng Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheng Cheng more than expected).

Fields of papers citing papers by Sheng Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheng Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheng Cheng. The network helps show where Sheng Cheng may publish in the future.

Co-authorship network of co-authors of Sheng Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Sheng Cheng. A scholar is included among the top collaborators of Sheng Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheng Cheng. Sheng Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, Yingying, Liangan Chen, Xianhui Ma, et al.. (2025). Danshensu enhances autophagy and reduces inflammation by downregulating TNF-α to inhibit the NF-κB signaling pathway in ischemic flaps. Phytomedicine. 137. 156378–156378. 7 indexed citations
2.
Zhang, Kaiwen, et al.. (2025). Thermoresponsive hydrogel dressings for precision drug release under physiological conditions. European Polymer Journal. 237. 114178–114178.
3.
Chen, Wenyi, Xinyi Chen, Qigu Yao, et al.. (2025). Mesenchymal stem cell-derived extracellular vesicles attenuate periductal fibrosis by inhibiting Th17 differentiation in human liver multilineage organoids and Mdr2−/− mice. Journal of Nanobiotechnology. 23(1). 546–546. 1 indexed citations
4.
Wang, Xinghuan, Sheng Cheng, Deying Chen, et al.. (2024). Serum metabolomics reveals the effectiveness of human placental mesenchymal stem cell therapy for Crohn's disease. Talanta. 277. 126442–126442. 2 indexed citations
5.
Ding, Lifeng, Qiming Zheng, Ruyue Wang, et al.. (2023). Exosome‐derived circTFDP2 promotes prostate cancer progression by preventing PARP1 from caspase‐3‐dependent cleavage. Clinical and Translational Medicine. 13(1). e1156–e1156. 28 indexed citations
6.
Chen, Huilong, et al.. (2022). The Global, Regional, and National Burden and Trends of NAFLD in 204 Countries and Territories: An Analysis From Global Burden of Disease 2019. JMIR Public Health and Surveillance. 8(12). e34809–e34809. 33 indexed citations
7.
Wang, Lan, Qing Luo, Xianbin Su, et al.. (2022). Inhibition of Arid1a increases stem/progenitor cell-like properties of liver cancer. Cancer Letters. 546. 215869–215869. 10 indexed citations
8.
Zeng, Zhilin, Juan Zhan, Kaimin Zhang, Huilong Chen, & Sheng Cheng. (2022). Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World Journal of Urology. 40(3). 755–763. 103 indexed citations breakdown →
9.
Ding, Lifeng, Ruyue Wang, Qiming Zheng, et al.. (2022). circPDE5A regulates prostate cancer metastasis via controlling WTAP-dependent N6-methyladenisine methylation of EIF3C mRNA. Journal of Experimental & Clinical Cancer Research. 41(1). 187–187. 50 indexed citations
10.
Ren, Liangliang, Minxiao Jiang, Dingwei Xue, et al.. (2022). Nitroxoline suppresses metastasis in bladder cancer via EGR1/circNDRG1/miR-520h/smad7/EMT signaling pathway. International Journal of Biological Sciences. 18(13). 5207–5220. 20 indexed citations
11.
Ding, Lifeng, Ruyue Wang, Huan Wang, et al.. (2022). circPHF16 suppresses prostate cancer metastasis via modulating miR-581/RNF128/Wnt/β-catenin pathway. Cellular Signalling. 102. 110557–110557. 12 indexed citations
13.
Ding, Lifeng, Ruyue Wang, Danyang Shen, et al.. (2021). Role of noncoding RNA in drug resistance of prostate cancer. Cell Death and Disease. 12(6). 590–590. 50 indexed citations
14.
Ding, Lifeng, Ruyue Wang, Danyang Shen, et al.. (2021). PIWI-interacting RNA 57125 restrains clear cell renal cell carcinoma metastasis by downregulating CCL3 expression. Cell Death Discovery. 7(1). 333–333. 18 indexed citations
15.
Shen, Danyang, Youyun Zhang, Qiming Zheng, et al.. (2020). A Competing Endogenous RNA Network and an 8-lncRNA Prognostic Signature Identify MYO16-AS1 as an Oncogenic lncRNA in Bladder Cancer. DNA and Cell Biology. 40(1). 26–35. 6 indexed citations
16.
Cheng, Sheng, Qiming Zheng, Liwei Xu, et al.. (2020). Management of major vascular injury in laparoscopic urology. SHILAP Revista de lepidopterología. 3(4). 107–110. 1 indexed citations
17.
Zeng, Zhilin, Sheng Cheng, Huilong Chen, et al.. (2017). Activation and overexpression of Sirt1 attenuates lung fibrosis via P300. Biochemical and Biophysical Research Communications. 486(4). 1021–1026. 64 indexed citations
18.
Chen, Huilong, Xiang-Qin Xu, Sheng Cheng, et al.. (2016). CXCR4 inhibitor attenuates ovalbumin-induced airway inflammation and hyperresponsiveness by inhibiting Th17 and Tc17 cell immune response. Experimental and Therapeutic Medicine. 11(5). 1865–1870. 25 indexed citations
19.
Chen, Huilong, Xiang-Qin Xu, Sheng Cheng, et al.. (2015). CXCR4 inhibitor attenuates allergen-induced lung inflammation by down-regulating MMP-9 and ERK1/2.. PubMed. 8(6). 6700–7. 33 indexed citations
20.
Cheng, Sheng. (2010). Anaphylactic shock with liver damage caused by levofloxacin injection. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026